Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: 

• Introduction (0:00)
• Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28)
• Long-Term Outcomes with Metastatic TNBC (11:55)
• Side Effects and Complications of Treatment (24:42)
• Dose Reduction (30:27)
• Working While Receiving Treatment (32:24)
• Support for Minor Children and Grandchildren (37:12)
• Second Opinions and Self Advocacy (42:53)
• Recording Clinic Visits; Complementary Therapies; Nutrition (48:38)
• Living Wills and Advanced Directives (55:41)

Please take our survey

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17)
• Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51)
• CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01)
• Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46)
• Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44)

CME information and select publications

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

• Introduction (0:00)
• Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53)
• Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45)
• Managing MF for Patients with Anemia — Dr Yacoub (59:47)
• Future Directions in the Management of MF — Dr Fleischman (1:27:53)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics:

• Introduction (0:00)
• Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17)
• Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54)
• Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59)
• Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16)
• Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30)

CME information and select publications

Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:

• Introduction (0:00)
• Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
• Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
• Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)

CME information and select publications

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

• Introduction (0:00)
• Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48)
• Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52)
• Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41)
• Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57)
• Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50)

CME information and select publications

Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21)
• Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36)
• Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58)
• Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52)
• Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Prof Giuseppe Curigliano, Dr Hope S Rugo and Dr Antonio C Wolff, including the following topics:

• Introduction (0:00)
• Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff (2:28)
• Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia (23:16)
• Practical Applications of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer — Prof Curigliano (51:31)
• Future Directions for HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Breast Cancer — Dr Rugo (1:11:57)

CME information and select publications

Featuring perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

• Introduction (0:00)
• Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26)
• Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53)
• Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48)
• Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52)
• Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:

• Introduction (0:00)
• Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
• Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
• Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)

CME information and select publications